about
Immediate effects of fluvastain on circulating soluble endothelial protein C and free tissue factor pathway inhibitor in acute coronary syndromesThrombopoietin as a drug: biologic expectations, clinical realities, and future directions.Unchanged global fibrinolytic capacity during the course of hematopoietic stem cell transplantation.Effect of platelet count on secretion capacity: formulization and use of the formulae for evaluation of platelet secretion in thrombocytopenic patients.The adhesion molecules of L-selectin and ICAM-1 in thrombocytosis and thrombocytopenia.Pathological haemostasis and "prothrombotic state" in Behçet's disease.A new candidate as a hemostatic agent for difficult situations during variceal bleeding: Ankaferd blood stopperAnkaferd blood stopper is more effective than adrenaline plus lidocaine and gelatin foam in the treatment of epistaxis in rabbits.Rethinking leptin and insulin action: therapeutic opportunities for diabetes.Circulating CD4+CD25+ regulatory T cells in the pathobiology of ulcerative colitis and concurrent primary sclerosing cholangitis.Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature.Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis.Increased circulating soluble P-selectin in polycystic ovary syndrome.No alteration in the PFA-100 in vitro bleeding time induced by the Ginkgo biloba special extract, EGb 761, in elderly patients with mild cognitive impairment.Cytarabine-induced fever complicating the clinical course of leukemia.Oral high-dose ankaferd administration effects on gastrointestinal system.Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level.The Dual Diverse Dynamic Reversible Effects of Ankaferd Blood Stopper on EPCR and PAI-1 Inside Vascular Endothelial Cells With and Without LPS Challenge.Impaired haemostatic kinetics and endothelial function in Behçet's disease.Ankaferd hemostat in the management of gastrointestinal hemorrhages.Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy.Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma.The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model.Perianal infections in patients with leukemia: importance of the course of neutrophil count.Concurrent presentations of the sarcoidosis, tuberculosis and lymphoma in a single patient.Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behçet's disease: evidence of a prethrombotic state.Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state.Autoimmune hemolytic anemia in Philadelphia positive chronic myeloid leukemia with t(7;14) anomaly after 5 years of interferon alpha treatment.Echocardiographic dilemma: misleading thrombus appearance due to cavitation with intravascular hemolysis on a mechanical prosthetic valve.Evisceration of the eye in a renal transplant recipient with cytomegalovirus chorioretinitis.The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment.Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability.Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.Seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus antibodies in Turkish patients with hereditary coagulation factor deficiencies.Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia.Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.Lack of association between familial Mediterranean fever and angiotensin converting enzyme gene polymorphism.Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?A comparison of Jurkat cell-reactive anti-T lymphocyte globulin and fetal anti-thymocyte globulin preparations in the treatment of aplastic anemia.
P50
Q28190720-C29291AA-0418-45DC-AAC6-D03713E68AABQ33344528-D383C0D4-4CE5-4E9D-B9E9-28864C89AAB9Q33370814-99E48C17-30DA-4929-8B13-3E7CB2B61F75Q33381388-8BD81653-C36B-4FFA-906A-8A86B3CDD5B7Q33387278-9E017A30-D113-4261-AB74-78874EEABDDCQ34604578-FE605B6C-6D26-48CF-91F5-6F32631A7E93Q34996037-A296FD34-B5FB-49EC-BFC7-E056CD5F357EQ35125534-01C8E48B-F458-446F-9700-FCB6C008A963Q36291212-D0AD8DDD-2C30-4816-A0B9-778C18A589EDQ36865862-59AB857C-9228-4190-B161-DCB8172BBAEAQ37391389-783FCF74-4263-4D91-B41D-C3C8960F9892Q38060210-A5E6A565-D034-41AC-9AEB-843BD1A74DDAQ39997593-4749EBCC-AC72-48C5-9957-AC03658DA7CBQ40412051-871F74A6-EBD0-475F-96F5-F06BF82CBAA3Q40518563-C02A7E32-D403-40E6-895E-276EF64EAA07Q41506776-DA39E114-D5D2-4E11-99AE-BF659B73B5BEQ41913676-57913856-CE45-4DC3-A08F-03FC20D4A73FQ42105285-A424F961-0BB2-4484-9C22-787FC74343ECQ42526978-DE88659B-14AC-44FB-AAF4-1A215D9715E6Q42591140-441A64B3-F792-45F1-B660-E6DC5EBCE2E1Q42942364-DFA93C43-AC41-4BEF-9997-96F72890D102Q43248998-2C5F34B9-BCEE-49EB-B62E-0E0C688AE6AEQ43298064-62843ED7-5C8F-4D37-B213-AE51D9D06CC7Q43563866-72DCD6E9-D9F5-40B3-B2FC-320FD61722BBQ43832015-2929DC72-A8EB-4FF2-92F1-2304D24D1987Q43885139-E8EFB336-8E39-446A-BB28-C9874D02388BQ44071017-337C5CB0-5BFD-4691-8B7A-F8365107F8E5Q44089107-2107F56E-0B7F-4761-B6D7-31B47B388B97Q44202427-F8956345-6189-406F-A7E2-A9AAF8EAAB2EQ44366205-E65F6AFC-EC68-44C0-9F7F-B0202874D20DQ44375363-A61540C9-3DAC-42C5-80E2-BF52A0B6C134Q44394903-37DDAA80-F97B-4B36-847A-E7F3A45AC75EQ44458096-8147778B-0AB5-44A7-BCC0-C156A84D474FQ44541027-1D1F5169-DCCA-4C6D-98E4-4F566B602BC6Q44620933-B0A15F15-5254-4F1F-83A4-7F4B9BC6BCF2Q44892477-F3E5C0E2-013D-4A12-B930-749AF810C4B5Q44912433-7CEA3D1A-CF1B-44AD-ACC5-229CC8BDC32DQ45115587-25EB9416-18A8-4EFE-9323-ABD139CD1797Q45133923-8DEA7CB3-9A74-4EF0-9181-3518A09A4FB5Q45415875-49EB8C9A-ADF1-4BF7-BEF4-ADB0202A615A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ibrahim Celalettin Haznedaroglu
@ast
Ibrahim Celalettin Haznedaroglu
@en
Ibrahim Celalettin Haznedaroglu
@es
Ibrahim Celalettin Haznedaroglu
@sl
type
label
Ibrahim Celalettin Haznedaroglu
@ast
Ibrahim Celalettin Haznedaroglu
@en
Ibrahim Celalettin Haznedaroglu
@es
Ibrahim Celalettin Haznedaroglu
@sl
prefLabel
Ibrahim Celalettin Haznedaroglu
@ast
Ibrahim Celalettin Haznedaroglu
@en
Ibrahim Celalettin Haznedaroglu
@es
Ibrahim Celalettin Haznedaroglu
@sl
P1053
B-7408-2009
P106
P21
P31
P3829
P496
0000-0001-8028-9462